Aptose Biosciences (APTO) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

APTO Aptose Biosciences

Watchlist

0.2790
+0.1088+63.92%

Close Dec 20 16:00 ET

0.2250
-0.0540-19.35%

Post 20:01 ET

16.61MMarket Cap-0.10P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Canada Net Change Percentage Gainers & Losers
Dow JonesDec 20 12:31 ET
Trending Stocks Today | My Size Soars 333.33%
Moomoo NewsDec 20 12:10 ET
Wall Street Set to Open Lower Friday; Key Inflation Data Lower Than Expected
MT NewswiresDec 20 09:12 ET
Top Premarket Gainers
MT NewswiresDec 20 08:04 ET
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
BenzingaDec 20 06:08 ET
Trending Stocks Today | Nvni Group Soars 85.39% Pre-Market
Moomoo NewsDec 20 04:25 ET

Comments

RocketRider

Yesterday 17:46

APTO Analysis

Aptose Biosciences Inc. (APTO) is a clinical-stage biotechnology company specializing in developing targeted therapies for hematologic malignancies.
Factors Influencing a Potential Rebound:
1. Clinical Developments:
• Tuspetinib Progress: Aptose’s lead compound, tuspetinib, has shown promise in treating acute myeloid leukemia (AML). Recent preclinical data demonstrate its unique mechanism of action and potential effectiveness, especially when combined with venetoclax.
2. Financi...

RocketRider

Yesterday 17:43

Positive!🚀

$Aptose Biosciences (APTO.US)$
Aptose Biosciences Inc. has announced the publication of preclinical data in the Cancer Research Communications journal, detailing the unique mechanism of action of their lead compound, tuspetinib (TUS), and its potential in treating acute myeloid leukemia (AML).
Key Findings:
• Selective Kinase Inhibition: Tuspetinib targets specific oncogenic kinases associated with AML, including SYK, JAK1/2, RSK2, mutant KIT, and both wild-type and mutant forms of FL...